BACKGROUND: The purpose of this study was to investigate the performance of the Memorial Sloan Kettering Cancer Center salivary carcinoma nomograms predicting overall survival, cancer-specific survival, and recurrence with an external validation dataset. METHODS: The validation dataset comprised 123 patients treated between 2010 and 2015 at our institution. They were evaluated by assessing discrimination (concordance index [C-index]) and calibration (plotting predicted vs actual probabilities for quintiles). RESULTS: The validation cohort (n = 123) showed some differences to the original cohort (n = 301). The validation cohort had less high-grade cancers (P = .006), less lymphovascular invasion (LVI; P < .001) and shorter follow-up of 19 months versus 45.6 months. Validation showed a C-index of 0.833 (95% confidence interval [CI] 0.758-0.908), 0.807 (95% CI 0.717-0.898), and 0.844 (95% CI 0.768-0.920) for overall survival, cancer-specific survival, and recurrence, respectively. CONCLUSION: The 3 salivary gland nomograms performed well using a contemporary validation dataset, despite limitations related to sample size, follow-up, and differences in clinical and pathology characteristics between the original and validation cohorts.
BACKGROUND: The purpose of this study was to investigate the performance of the Memorial Sloan Kettering Cancer Center salivary carcinoma nomograms predicting overall survival, cancer-specific survival, and recurrence with an external validation dataset. METHODS: The validation dataset comprised 123 patients treated between 2010 and 2015 at our institution. They were evaluated by assessing discrimination (concordance index [C-index]) and calibration (plotting predicted vs actual probabilities for quintiles). RESULTS: The validation cohort (n = 123) showed some differences to the original cohort (n = 301). The validation cohort had less high-grade cancers (P = .006), less lymphovascular invasion (LVI; P < .001) and shorter follow-up of 19 months versus 45.6 months. Validation showed a C-index of 0.833 (95% confidence interval [CI] 0.758-0.908), 0.807 (95% CI 0.717-0.898), and 0.844 (95% CI 0.768-0.920) for overall survival, cancer-specific survival, and recurrence, respectively. CONCLUSION: The 3 salivary gland nomograms performed well using a contemporary validation dataset, despite limitations related to sample size, follow-up, and differences in clinical and pathology characteristics between the original and validation cohorts.
Authors: Jian Ji Pan; Wai Tong Ng; Jing Feng Zong; Sarah W M Lee; Horace C W Choi; Lucy L K Chan; Shao Jun Lin; Qiao Juan Guo; Henry C K Sze; Yun Bin Chen; You Ping Xiao; Wai Kuen Kan; Brian O'Sullivan; Wei Xu; Quynh Thu Le; Christine M Glastonbury; A Dimitrios Colevas; Randal S Weber; William Lydiatt; Jatin P Shah; Anne W M Lee Journal: Cancer Date: 2016-07-19 Impact factor: 6.860
Authors: José F Carrillo; Rafael Vázquez; Margarita C Ramírez-Ortega; Ana Cano; Francisco J Ochoa-Carrillo; Luis F Oñate-Ocaña Journal: Cancer Date: 2007-05-15 Impact factor: 6.860
Authors: Safina Ali; Frank L Palmer; Changhong Yu; Monica DiLorenzo; Jatin P Shah; Michael W Kattan; Snehal G Patel; Ian Ganly Journal: Ann Surg Oncol Date: 2013-10-17 Impact factor: 5.344
Authors: Safina Ali; Frank L Palmer; Changhong Yu; Monica DiLorenzo; Jatin P Shah; Michael W Kattan; Snehal G Patel; Ian Ganly Journal: JAMA Otolaryngol Head Neck Surg Date: 2013-07 Impact factor: 6.223
Authors: Kaveh Zakeri; Huili Wang; Jung Julie Kang; Anna Lee; Paul Romesser; Nader Mohamed; Daphna Gelblum; Eric Sherman; Lara Dunn; Jay Boyle; Richard Wong; Linda Chen; Yao Yu; C Jillian Tsai; Sean M McBride; Nadeem Riaz; Nancy Lee Journal: Head Neck Date: 2021-02-19 Impact factor: 3.821